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Introduction 
In this case analysis, the authors contend that when 
knowledge is widely  expanding, new information is 
needed, and availability of internal resources is limited or 
difficult to evaluate, organizations reach out to external 
alliances in search of relevant support to deal with 
uncertainty and issues arising from environmental 
changes. Four hypotheses were presented and tested 
on a sample of biotechnology firms over a five year 
period (1990-1994). 
1.Collaboration and Organizational Learning 
Learning through Networks 
Hypothesis 
Hypothesis 1: Collaboration with alliances and experience 
would generate more alliances, and network expansion.  
Hypothesis 2. Collaboration, experience, and network 
expansion increase central connectivity.  
Hypothesis 3: Central connectivity and network 
collaboration experience increases firm growth.  
Hypothesis 4: Central connectivity increases collaboration 
with alliances.  
The Biotechnology Industry 
Biotechnology is a relatively young science based 
industry and the hypothesis has been derived in this 
context. The work of Watson and Crick in the field of 
molecular biology in the early 1950’s had greatly 
contributed to subsequent developments in the field. 
Biotechnology can impact various other scientific 
fields. This type of technology has been commercially 
exploited with sales growing in millions.  
2. The Method 
Data.  This empirical analysis was conducted to explain the organizational agreement system that shapes learning in biotechnology. The agreements were legitimate contracts 
that bounded companies together and involved mutual expensive investments. A relational database containing separate files for human therapeutics and diagnostics, the inter-
organizational agreements and the parties involved were used.  The data was compiled using Bioscan, an independent industry directory that provided information about different 
types of companies, their products and current research. Other industrial directories were also consulted to fill in the missing information gap. A sample of about 225 independently 
owned companies was gathered in the research-driven of Dedicated Biotech Firms (DBF) in the field of human therapeutics. 
 
 
 
 
 
Operationalizations and Measures 
Dependent  variables are based on Hypotheses 1-4 which 
consists on the diverse increment of alliances, central 
connectivity and rate of growth indicated as follows: 
Number of R&D ties at time t + 1 - The number of active 
Research and Development (R&D) alliances of X firm.  
Number of non-R&D ties at time t + 1 - Passive R&D 
Companies. Number of diverse ties at time t + 1- The network 
portfolio diversity reflecting the number of times X firm engaged 
in collaborative activities per year and it’s expressed by Blau’s 
index of heterogeneity formula. Y= 1-∑p2 (each # of collaborative 
project squared per year).  
Central connectivity at time t + 1 -Connection between 2 DBF’s 
was measured using UCINET IV and counted as either a direct 
tie (degree 1), when firms were directly connected and indirect tie 
(degree 2), when firms were connected through a common 
partner, As shown in Figure 1, firms B & C have a direct tie with 
firm A and connection level 1, but firm D has an indirect tie and a 
level  2. 
Independent variables 
Collaborative R&D experience at time t +1 was computed 
from the time the firm established the alliance minus the first 
date.  
Non-R&D network experience at time t + 1 was counted from 
the time the firm established a tie for any non-R&D purposes. 
Control variables for age and size were used to prove diversity 
and centrality validity as well as to minimized errors, and in order 
to assure that they could be treated as outcomes rather than 
predictors of the way in which networks behaved. 
Statistical methods 
Variables were measured within the firm using a regression 
statistic analysis. DBF were observed for a five years  time 
period instead of using a random sample. To reduce the effect of 
conditions that could not be determined or observed at the time, 
fixed variables were used to control two assumptions the were 
considered :  1st assumption: Learning gradually occurs within 
organizations and the actors are the recipient of knowledge.  For 
instance, large firms have more R&D connections and diverse 
portfolio network because of previous successful experiences.  
To reduce the unobserved differences among firms, a dummy 
variable for each firm was used to control the deviation between 
the dependent and independent variables within firms.  
2nd assumption: Learning engages firms and networks in a joint 
co-evolution. Using a “fixed-effect specification equation, 
variables were fixed to isolate the effect of the firm and the year. 
3. Results 
The findings supported the following: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypothesis 1:  The positive effects of R&D collaborations was 
shown on finance, marketing, clinical, investment, and supply. It 
supported that collaborative R&D and experience generates 
diverse ties and an increment on diverse ties. It did not show 
that an increase in experience would increase the number of 
Non-R&D ties. 
Hypothesis 2: The positive effect of central connectivity is 
shown by the degree of closeness and centrality as well as 
membership component of the R&D, Non-R&D and diverse ties. 
Hypothesis 3: The degree-centrally had a positive correlation 
on the firm growth showing an increase in the firm size and 
publicly traded status. 
“Hypothesis 4: The number R&D ties were considerably 
elevated. The coefficient of correlation between closeness 
centrally and R&D ties were significantly high scoring at or 
beyond the 0.5 level. 
Firms with ties: 
Were older and larger, suggesting 
that firms with ties tend to grow 
faster than firms without ties 
Opted to continue a relationship 
with their old alliances after their 
agreement ended.  
Initiated different projects with the 
same alliance 
Showed significant growth 
Increased new diverse ties 
 Were publicly traded at a larger 
percentage than firms without ties 
Firms without ties  
Dropped by 50% 
Were rare 
Figure1- Central Connectivity  
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Table 2- Hypothesis Results  
This analysis supports the notion that collaboration has a significant effect on the growth of networks when relevant information is widely expanded, but unavailable within the 
internal environment. The authors emphasize that a collaborative interconnectivity between networks fosters knowledge, helps firms co-evolve in the learning process and triggers 
innovation. At the time this study was completed is was still early to make additional predictions in the Biotech science field. Many of the founding firms in the business did not yet 
reach the 20 years. The result of the study was limited to companies that started after 1990. Therefore, the networking pattern that developed within the five years period 
encompassing the study was yet unknown. Current results show that biotech firms can benefit from generating alliances, but the tangible outcomes of the network ties can not be 
simply determined. The findings show that age and size did not affect the pattern of collaboration.  Age did not predict experience, and size was only an outcome in the networking 
process. Some of the benefits of the general practice of collaboration include: increased collaborative project management skills, competencies, new project awareness, central 
connection as well as enhanced reputation (Powell, Koput, & Smith-Doerr, 1996). Although the study was conducted about fifteen years ago, increasing literature continues to 
corroborate with the fact that “Collaboration is the new competition.” 
4. Conclusion 
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Membership in the main component at time t +1 - N groups of firms that are connected to an X firm in 
the group of degree 1 or distance 2.  
Degree of centrality at time t + 1 was measured depending on the number of N firms connected to an X 
firm, regardless the strength of their connection.  
Closeness centrality at time t + 1 was computed as the reciprocal of the sum of the degree of distance 
between firms and their direct access to other firms in the network.  
Growth at time t + 1 was measured using the size and company ownership status method. Size was 
determined by the total number of employees. Ownership status was verified by the firm publicly-traded 
condition. 
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